Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, abrupt discontinuation of GLP-1 RAs during the perioperative period may worsen glycemic control, increase insulin requirements, and negate established cardiometabolic and renal benefits, potentially introducing additional perioperative risk [7].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some professional bodies recommend considering withholding GLP‐1 RAs before surgery but emphasise that there is limited evidence available about the effectiveness of this strategy [16, 21, 22, 23].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternative strategies, including changing pre‐operative fasting guidance, using prokinetic drugs and implementing routine point‐of‐care ultrasound to mitigate risk, have been suggested, but their effectiveness also remains uncertain [21, 26].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the initial guidance for preoperative management of GLP-1 RAs advocated a conservative strategy, recommending temporary discontinuation for safety considerations.”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently, multi‐societal consensus statements across the UK, USA and Australia support a shared decision‐making approach for minimising risk among patients using GLP‐1 RAs [18, 21, 22].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“Further, GLP-1RAs induce common side effects of nausea, vomiting, abdominal pain, and constipation, which may complicate the diagnosis and treatment of pre-and post-operative disease states that share these symptoms [10].”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety [1, 2].”
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285 · cited 1×
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety [1, 2].”
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259 · cited 1×
“…can be utilized in patients when there is concern for delayed gastric emptying based on clinical symptom review as described in Recommendation 1a [5, 11, 15]. b) When clinical concern for retained gastric contents exists on the day of the procedure, point-of-care gastric ultrasound could be used…”
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report
Klein, S. R., & Hobai, I. A. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02440-3 · Cited by 207
Gulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153
Hashash, J. G., Thompson, C. C., & Wang, A. Y. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.002 · Cited by 140 · cited 3×
“…be utilized in patients when there is concern for delayed gastric emptying based on clinical symptom review as described in Recommendation 1a [5, 11, 15]. b) When clinical concern for retained gastric contents exists on the day of the procedure, point-of-care gastric ultrasound could be used to…”
Self-citationSherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132 · cited 1×
“An increasing safety concern has developed amongst providers regarding the perioperative use of GLP-1RA due to delayed gastric emptying and subsequent residual gastric contents on the day of the procedure despite traditional fasting [4–6].”
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“85,89 Further prospective studies are needed to clarify perioperative risks associated with GLP-1 RA use and inform individualized management.”
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s016 · Cited by 80
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“…contents and risks for aspiration pneumonia have led to multiple guidelines and recommendations surrounding perioperative assessment and individualized recommendations surrounding continuation or cessation of GLP-1 medicines in people undergoing elective endoscopy or surgical procedures 78 .”
Castrillon, J., Rele, S., Sumithran, P., Hii, M., Thuraisingam, S., Spelman, T., Phan, T., Choong, P., Dowsey, M., & Shadbolt, C. (2025) · Anaesthesia · doi:10.1111/anae.16601 · Cited by 65
“Alternative strategies, including changing pre-operative fasting guidance, using prokinetic drugs and implementing routine point-of-care ultrasound to mitigate risk, have been suggested, but their effectiveness also remains uncertain [21, 26].”
InfluentialJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“Multi-society consensus guidelines have, in general, recommended an individualized approach toward the decision to withhold GLP-1RA therapy (46).”
Daneshgaran, G., Shauly, O., & Gould, D. J. (2025) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojaf056 · Cited by 43
“38 Before surgery, the risk of delayed gastric emptying and aspiration should be evaluated by considering drug dosage, titration phase, frequency of dosing, and the presence of gastrointestinal symptoms or other medical comorbidities that may delay gastric emptying.”
InfluentialHolding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Ahmad, A. I., Garg, S., Jacobs, J., Ansari, Z., Al-Din, T. J., Almomani, A., Valencia, S., Vargo, J., Chatterjee, A., Siddiki, H., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0027 · Cited by 24
Wu, H.-L., Chen, J., Cata, J. P., Hsieh, C.-H., Cherng, Y., & Tai, Y. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.08.003 · Cited by 22
Haskins, S. C., Bronshteyn, Y. S., Ledbetter, L., Arzola, C., Kalagara, H. K. P., Hardman, H. D., Panzer, O. P. F., Weber, M. M., Heinz, E. R., Boublik, J., et al. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-106346 · Cited by 25
“99 There is great interest in the role of gastric POCUS in this patient population, and the authors recognize that as more evidence emerges, recommendations may change.”
GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
Ramanathan, R., Lee, J. Y., Dalton, J., Lin, R. T., Lee, I., Gonzalez, C., Shaw, J. D., Schroeder, G. D., Kepler, C. K., Spitnale, M. J., et al. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.01287 · Cited by 17
Vetrugno, L., Deana, C., Porto, A. D., Boero, E., Bellini, V., Biasucci, D. G., & Bignami, E. G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00237-y · Cited by 14
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
Crespo, J., Rodríguez-Duque, J. C., Iruzubieta, P., Cerda, E. C. M., & Velasco, J. A. V.-R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155597 · Cited by 9
“A ≥ 7-day hold is now reserved for a narrowly defined subgroup: patients with prior failed preparations despite intensified regimens or those exhibiting overt symptoms of upper gastrointestinal dysmotility [36].”
InfluentialWeight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Gastric point‐of‐care ultrasound in the GLP‐1 receptor agonist era: clinical impact and competency
Kelly, D. N., Pentyala, S., & Haskins, S. C. (2025) · Anaesthesia · doi:10.1111/anae.16548 · Cited by 6
Salihu, A., Fournier, S., Hugelshofer, S., Liabot, Q., Weerts, V., Τζίμας, Γ., Rancati, V., Ferlay, C., Zimmerli, A., Müller, O., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040445 · Cited by 5
“5,32 Thus, more data are required to better understand whether fasting should still be recommended in the presence of such medication even in the context of mild procedural sedation.”
Non-insulin diabetes medicines: a narrative review for anaesthetists and intensivists
Tinsley, S. L., Frank, C., Stubbs, D. J., Dhatariya, K., Knaggs, R., & Levy, N. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.050 · Cited by 7
“18 At present, the evidence base remains limited to make any recommendations.”
Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry
McKenzie, C., DeBernardo, A., & Schwartz, P. (2025) · Anesthesia Progress · doi:10.2344/anpr-72-1-anpr_agonists · Cited by 5
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
“83,84 Volume status and hemodynamic management are also central in AIS, particularly in older adults and those with HF/CKD, and should be systematically assessed in trials.”
Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis
Collaço, B. G., Gomez-Cabello, C. A., Haider, S. A., Genovese, A., Prabha, S., Rinker, B. D., Forte, A. J., & Elegbede, A. I. (2026) · BMC Plastic and Reconstructive Surgery · doi:10.1186/s44452-026-00024-w · Cited by 9
“Moreover, Albanese et al. (2025) was the only study to adhere to the American Society of Anesthesiologists (ASA) protocol [42, 43], discontinuing GLP-1 therapy one week prior to surgery [24].”
Khan, I. (2025) · BDJ · doi:10.1038/s41415-025-8563-0 · Cited by 5
Updates in chronic kidney disease management: A systematic review
Ammar, A., Edwin, S. B., Whitney, R., Lipari, M., & Giuliano, C. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70014 · Cited by 3
Kothari, P., Vanneman, M. W., Choi, C. H., Diehl, R., & Fielding‐Singh, V. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.05.014 · Cited by 3
Khak, M., Adams, J. A., Hozien, M., & Ilyas, A. M. (2025) · Cureus · doi:10.7759/cureus.89183 · Cited by 4
“These findings have been echoed by recent multisociety guidelines issued by the American Society of Anesthesiologists and collaborating organizations, which recommend holding GLP-1 RAs prior to surgery, especially in patients receiving general anesthesia or those at higher risk of aspiration [6].”
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Levy, N., Tinsley, S. L., & Dhatariya, K. (2024) · Anaesthesia · doi:10.1111/anae.16509 · Cited by 2
Li, J., Mohamed, B. A., Huang, S., & Peng, Y. G. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2494646 · Cited by 3
“The decision to withhold GLP-1 RAs should balance the surgical and medical risks of inducing a potentially hazardous metabolic state, such as hyperglycemia 80 .”
GLP-1 Receptor Agonists and Perioperative Care: Comment
Mizubuti, G. B., Jones, P. M., & Hobai, I. A. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005427 · Cited by 2
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2
Kukanti, C., Chowdhury, S. R., & Singh, G. P. (2025) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-025-05485-6 · Cited by 2
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
“Meanwhile, abrupt discontinuation of GLP-1 RAs during the perioperative period may worsen glycemic control, increase insulin requirements, and negate established cardiometabolic and renal benefits, potentially introducing additional perioperative risk [7].”
InfluentialGlucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery
Hsu, R. C., Han, E., Swartz, S., & Pacis, M. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006035 · Cited by 1
Box, M. W., Puga, T. B., Werthmann, N. J., Liu, Y., & Riehl, J. T. (2025) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-25-00312 · Cited by 1
“These are contextual factors emphasized in the 2024 American Society of Anesthesiologists guidelines, 36 which suggest continuing GLP-1RA through the day of surgery in low-risk patients.”
Le, K., Prasad, S., & Shah, R. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2583025 · Cited by 2
Zapp, C., Downer, D. M., Levine, A., Parker, N., Zapp, M., Downer, D. M., & Levine, L. (2026) · Cureus · doi:10.7759/cureus.102921 · Cited by 2
“Subsequently, in October 2024, a multispecialty society, including the ASA, issued a new statement stating that most patients (with modifications to NPO status or gastric ultrasound testing) could continue their GLP-1RA before elective surgery [5].”
Hasan, I., Bessette, L. G., Jacquemyn, X., Wang, Y., subramaniam, K., Hasan, Z., Thoma, F. W., Ogami, T., Bonatti, J. O., Kaczorowski, D., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.02.005 · Cited by 2
Somasundaram, S., Nightingale, J., Sreedharan, S., & Frauenfelder, C. (2026) · Ear Nose & Throat Journal · doi:10.1177/01455613261445013 · Cited by 1
Michell, E., Lange, A., & Ben‐Menachem, E. (2026) · Anaesthesia · doi:10.1111/anae.70220 · Cited by 1
Gallagher, M., Taylor, B., Mirro, I., Huynh, J., Snyder, J., & Palese, M. A. (2026) · Journal of Robotic Surgery · doi:10.1007/s11701-026-03454-x · Cited by 1
GLP-1 receptor agonist use and aspiration pneumonia risk following endovascular thrombectomy
Sardana, S., Mateti, N. R., Hackett, C., Singh, R., Bagga, S., Kotekal, D., Prahalad, A., Shakeel, H. A., Kamboj, N., Saim, M., et al. (2026) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2026-025486 · Cited by 1
Szarpak, L., Maslyk, M. M., & Aleksandrowicz, D. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.04.060 · Cited by 2
Hyung, B., Ye, X. Y., Chandrakumar, M., Lovshin, J. A., & Peacock, S. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70955 · Cited by 2
Al‐Majmuei, A., Alatoom, M., Abdullahi, F., Marza, L., Murjan, N. A., Qasmi, R. A., Al-Rahbi, T., AlOmar, H., Alsherooqi, R., & Arekat, D. Z. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02671-7 · Cited by 1
“In contrast, more recent multisociety guidance developed by the American Society for Metabolic and Bariatric Surgery, and the American Society for Gastrointestinal Endoscopy, support continuation of therapy in patients without signifi - cant gastrointestinal symptoms [11].”
Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?
Mishra, S., Persons, P. A., & Bersoux, S. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24110 · Cited by 2
Sen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Sidhu, N. S., & Hogg, R. M. G. (2025) · Anaesthesia Reports · doi:10.1002/anr3.70015 · Cited by 3
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Perioperative Medication Management
Rudy, M. D., & Grant, P. (2025) · doi:10.1093/med/9780197754153.003.0108
Hobai, I. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.03.015
GLP-1 Receptor Agonists and Perioperative Care: Reply
Joshi, G. P., LaMasters, T. L., & Kindel, T. L. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005428
Self-citationHypertension after solid-organ transplantation: special considerations for management
Feliberti, J. P., Alam, A., & Maulion, C. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001230
Barlowe, T. S., Gouker, L. N., Buse, J. B., Sandler, R. S., & Dougherty, M. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-025-00472-w
Perioperative management of patients on GLP-1 receptor agonist treatment: Risks and recommendations
Polo, E. S., Jiménez, I. R., Ahedo, N. A., & Fernández, M. S. (2025) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2025.501859
Polo, E. S., Jiménez, I. R., Ahedo, N. A., & Fernández, M. S. (2025) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2025.501859
Hacking, D. F., Baqar, S., Vaughan, R., & Craven, A. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355289
Practice changing updates in perioperative medicine literature 2024. A systematic review
Khambaty, M., Silbert, R. E., Stephenson, C. R., Bartlett, M. A., Regan, D. W., Sanchez, J. J., Sundsted, K. K., & Mauck, K. F. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.08.037
Managing patients taking glucagon-like peptide-1 receptor agonists: proceed with caution
Ovsak, G. G., & Gan, T. J. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.10.004 · Cited by 1
Seddio, A. E., Grauer, J. N., & Rubin, L. E. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.09.029
Prise en charge du surpoids et de l’obésité en préopératoire
Pardo, E. (2026) · Le Praticien en Anesthésie Réanimation · doi:10.1016/j.pratan.2026.02.007
Box, M. W., Puga, T. B., Poffenbarger, M., Liu, Y., & Riehl, J. T. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-026-04720-2
Associations between GLP 1 receptor agonist therapy and surgical wound healing in a high-risk cohortPreprint
Pullmann, D., Adams, J. C., Belostotsky, H., Mestvirishvili, T., Chiu, M. E., Oh, C., & Rabbani, P. S. (2026) · medRxiv · doi:10.64898/2026.04.21.26351321
Glucagon-like peptide-1 receptor agonists and periprocedural pulmonary aspiration: where are we now?
Hobai, I. A. (2026) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-026-03113-7
“Les plus récentes recommandations multisociétés 8 considèrent que seules certaines personnes sous AR GLP-1 présentent un risque accru et proposent plusieurs critères de strati fi cation du risque (voir ci-dessous), mais peu d ’ autres groupes ont adopté cette approche.”
Elawa, Z., Khalil, A., Kardousha, A., Elawwa, A., & Soliman, A. T. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113332
The Role of Gastric Ultrasound in Assessing Gastric Content and Aspiration Risk
Gahagan, K., Sharifi, N., Smith, C., & Brennan, M. (2026) · Current anesthesiology reports · doi:10.1007/s40140-026-00706-2
Rouse, M., Kokelaar, R., Lee, I., & Yeung, J. M. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.05.027
Ballotin, V. R., Ferreira, P. L. C., de Almeida, V. T., Borges, C. D. S., de Almeida, H. T., da Silva, R. G. P., Volquind, D., & Selistre, L. D. S. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.121449
Qian, Z., & Jiang, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351731
“The early-onset pattern (median TTO 30 days for most GLP-1RAs) suggests that close monitoring during the initial treatment period is warranted, with particular attention to symptoms of delayed gastric emptying including early satiety, postprandial fullness, and nausea [36,37].”
Shounthoo, R. S., Rasool, A., Bashir, H., Quraishi, A. U. N., Yousuf, I., & Ara, F. (2026) · Asian Journal of Medical Sciences · doi:10.71152/ajms.v17i7.5334
Park, H. J., Oh, Y. E., Chi, S. A., Kim, M., Kim, J. E., Hong, S. N., Min, B., Kim, Y.-H., Chang, D. K., Kim, T., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121313
Song, E. Y., Melton, M. S., Hammert, W. C., Li, N. Y., & Saltzman, E. B. (2026) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2026.05.008
Chauhan, V., Muppuri, I., Richert, A. C., & Kurnutala, L. N. (2026) · Journal of Ect · doi:10.1097/yct.0000000000001303
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Muthu, S., Viswanathan, V. K., Ponnusamy, D. V. K., Samuel, M. S., Chandra, S. K. R., Sharun, K., Hiatt, L., Manoharan, S. R. R., & Theiss, S. M. (2026) · European Spine Journal · doi:10.1007/s00586-026-10205-x · Cited by 1
Clear Liquids, Safer Procedures—Lessons from the OCULUS Trial—Reply
Ahmad, A. I., & Shah, T. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.3107
Caimi, E., Ghetti, E. M., Giovagnoli, F., Vaccari, S., Ceglia, G., Cavallero, M. F., Comunian, R., Giuli, R. D., Veronesi, A., Klinger, F. M., et al. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-06155-w
“Perioperative safety represents a second major thematic focus, particularly concerns related to delayed gastric emptying, nausea, glycemic variability, and aspiration risk during anesthesia [7, 15, 23].”
Bareera, S., Hussain, S. H., Momin, S. M., Ahmad, S. M., & Fayyaz, M. (2026) · BMC Plastic and Reconstructive Surgery · doi:10.1186/s44452-026-00033-9
“…interpretation because perioperative guidance has shifted from the initial ASA recommendation to hold weekly agents for 1 week before surgery toward updated guidance that emphasizes individualized assessment based on timing, gastrointestinal symptoms, dose escalation, and patient-level risk [2, 3].”
Anästhesieführung und präoperative Nüchternheit in der Gelenkchirurgie
Luger, M. F. (2026) · Arthroskopie · doi:10.1007/s00142-026-00858-7
Lai, H., Sun, T., & Yu, X. F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05161-1
“In particular, glucagon-like peptide-1 receptor agonists have attracted increasing attention because of their potential to delay gastric emptying and alter gastrointestinal transit [59, 60].”
Topcu, U., & Oto, F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03004-0
“This approach is consistent with current multi-society guidance from Kindel et al. and the SPAQI consensus statement by Oprea et al. [ 27, 28 ].”
InfluentialPerioperative Optimization Strategies in Major Genitourinary Cancer Surgery
Yellu, A., Weitzner, A. S., Cronin, C., Kim, J. K., & Lokeshwar, S. D. (2026) · Cancers · doi:10.3390/cancers18162588 · Cited by 1
“At the same time, discontinuation of GLP-1 RAs must be balanced against the risks of worsening glycemic control and the patient’s metabolic needs [65].”
InfluentialRead, D., Smith, A. C. T., Mountjoy, M. L., van Rensburg, D. C. J., Dijkstra, H. P., & Taylor, L. K. (2026) · Sports Medicine · doi:10.1007/s40279-026-02514-4
Kruthof, J., & Chau, A. M. T. (2026) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-026-03185-5
The Clinical Importance of Adequate Bowel Preparation
Oldfield, E. C., & Johnson, D. A. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70570
“…patients on GLP-1 agonists had significantly lower mean BBPS score (7.0 +/ − 1.9 vs. 7.5 +/ − 2.4, = p = 0.046), significantly higher percentage of IBP with BBPS 5 (15.5% vs. 6.6%, p = 0.01) and significantly higher rates of repeat colonoscopy due to IBP (18.9% vs. 11.1%, p = 0.041) [28, 29].”
InfluentialShen, N., Zhu, C., Wang, F., & Wu, M. (2026) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s623743
“22,23 This review summarizes the mechanisms of GLP-1RA-associated delayed gastric emptying, treatment-and patient-related risk modifiers, perioperative clinical evidence and its limitations, areas of agreement and uncertainty among major guidance statements, and a pharmacist-led implementation…”
Ripoll, J. G., Herrera, H. R., Zaremba, S., Maruniak, S. R., Ursoleo, J. D., Wieruszewski, P. M., & Ramakrishna, H. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.08.160
Ferraz, V. R., Dawoud, B., Mercier, P. A., & Mattei, T. A. (2026) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2026.100942
“Delayed gastric emptying has also prompted perioperative concerns regarding aspiration risk and anesthetic management [ 8 ].”
InfluentialO’Brien, E. M., Gallop, R., Washburn, M., Dumas, A., Como, N., Kilungya, F., Willi, S. M., & Lin, E. E. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.07.016 · Cited by 2
Trikha, A., & Khalil, M. (2026) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_419_26
Perioperative Considerations in Patients with Type 2 Diabetes Mellitus: A Narrative Review
Ascanio, D. J. M., Palacios-Rodríguez, M. A., Maldonado-Burbano, L. G., Arias-Pérez, J. C., Bravo-Echeverry, V., Fonseca, I., Martínez, B. F. N., Castillo-Rojas, R. A., & Carvajal-Mazuera, A. J. (2026) · Health Care & Global Health · doi:10.22258/hgh.v10i3.475
Préparation en vue d’une endoscopie digestive basse chez l’adulte
Pienkowski, P. (2026) · EMC - Gastro-entérologie · doi:10.1016/s1155-1968(26)49536-x
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“Current multisociety guidance recommends risk assessment rather than routine withholding of GLP-1 recep - tor agonists in every patient before surgery [68].”
Henz, R. C., Donato, A. C. G., Krambek, A. L. S., Filiciani, C. M., Mazzer, J. P. B., Dias, P. H. M., Bellucci, P. V. T., Franchette, L. G., & Machado, H. T. V. (2026) · Brazilian Journal of Health Review · doi:10.34119/bjhrvxnx-074
Ganapathy, K. D. K., Mostafa, S. A., Lane, B., Kurian, M., & Babwah, F. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm55387
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
“64 Higher ‐ risk patients may benefit from a 24 ‐ h clear liquid diet before upper endoscopy regardless of drug continuation status, as this strategy eliminated clinically significant RGV in all OCULUS subgroups.”
Dominiak, M., Niemczyk, W., Suwała, S., Gedrange, T., & Geller, V. (2026) · Biomedicines · doi:10.3390/biomedicines14102255
Sofronov, K. A., Marshalov, D. V., Kodatskiy, D. S., & Валерьевич, К. М. (2026) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology2026051114
Nosratzehi, M., Nosratzehi, S., & Rostami, M. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-06399-6
Covre, S. B., Campos, B. G., da Silva, V. D., Loureiro, J. M., Rodrigues, I., Pessoa, J. P. S., & Panciere, W. M. D. M. (2026) · Aurum Editora eBooks · doi:10.63330/aurumpub.068-054
Metadata
- Authors
- Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S., Joshi, G. P., LaMasters, T., & Representing the American Gastroenterological Association, A. S. F. M. A. B. S.
- Affiliations
- Medical College of Wisconsin (US)
- University of Virginia (US)
- The University of Texas Southwestern Medical Center (US)
- University of Michigan (US)
- Weill Cornell Medicine (US)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Tulane University (US)
- University of Iowa (US)
- Corresponding author
- Kindel, Tammy L.
- ORCID
- Venue
- Surgical Endoscopy
- Published
- 2024-10-29
- Volume
- 39
- Issue
- 1
- Pages
- 180-183
- ISSN
- 0930-2794 (ISSN-L)
- 1432-2218
- PMC
- PMC11666732
- OpenAlex
- W4403162749
- Cited by
- 98
- References
- 13
- Citations by year
- 2026: 57 · 2025: 40 · 2024: 1
- FWCI
- 32.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Surgical Endoscopy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Society of American Gastrointestinal and Endoscopic Surgeons
- American Gastroenterological Association
- American Society for Metabolic and Bariatric Surgery
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac, Anesthesia and Surgical Outcomes
- Keywords
- GLP-1 receptor agonists, perioperative care, surgical patients, diabetes mellitus, drug safety, clinical guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.